A Sponsor's Enhanced Review Obligations for Connected Transactions of the Listing Applicant

The Hong Kong market has entered a period of heightened regulatory scrutiny where the boundary between a sponsor’s due diligence obligations and the issuer’s ongoing disclosure duties is being actively redrawn. The 2024 and early 2025 enforcement actions by the Securities and Futures Commission (SFC) and the Stock Exchange of Hong Kong Limited (HKEX) have made one thing unequivocally clear: a sponsor’s work does not end at the point of listing. For connected transactions (CTs) involving a listing applicant, the sponsor’s enhanced review obligations now extend deep into the pre-IPO window and, in certain cases, into the immediate post-listing period. The SFC’s 2024 thematic inspection findings on sponsor due diligence, published in October 2024, specifically flagged deficiencies in how sponsors assess the arm’s length nature of pre-IPO investments and the commercial rationale for connected party arrangements. This shift is not merely procedural; it is a direct response to the market’s experience with high-profile listing failures where undisclosed or poorly characterised connected transactions eroded investor confidence. For sponsors holding Type 6 (Advising on Corporate Finance) and Type 6A licences, the operational question is no longer whether to review CTs, but how to structure a review framework that withstands the SFC’s forensic examination of the sponsor’s work product.

The Regulatory Foundation: Listing Rules and the SFC’s Expanded Mandate

HKEX Listing Rule Chapter 14A and the Sponsor’s Implied Duty

HKEX Listing Rule Chapter 14A governs connected transactions for listed issuers. For a listing applicant, however, the relevant period is not the post-listing life but the 12-month period immediately preceding the submission of the listing application. Rule 14A.10 states that any transaction entered into by a listing applicant with a connected person within this 12-month window, which would have been a CT had the applicant been listed at the time, must be disclosed in the prospectus. The sponsor’s obligation here is not merely to identify these transactions but to verify their terms, pricing, and commercial necessity. The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (the Code), specifically paragraph 17.6, requires a sponsor to exercise due diligence to form a reasonable belief that all information contained in the prospectus is true, accurate, and complete. This places the sponsor in a position of primary responsibility for the accuracy of CT disclosures, even where the transaction itself was entered into by the issuer’s pre-IPO board.

The practical implication is that a sponsor must build a CT review programme that begins at the start of the sponsor engagement, not at the draft prospectus stage. The SFC’s 2024 thematic report noted that in several cases, sponsors had relied solely on management representations about the nature of pre-IPO transactions without obtaining independent evidence of the counterparty’s identity, the transaction’s pricing benchmark, or the ultimate beneficial ownership structure. This is no longer acceptable.

The SFC’s 2024 Thematic Inspection Findings

The SFC’s October 2024 report, Thematic Inspection of Sponsor Due Diligence on Connected Transactions, examined 15 sponsor engagements covering 22 listing applications. The findings were stark: in 8 of the 15 engagements (53.3%), the SFC found that the sponsor had failed to adequately document the steps taken to verify the arm’s length nature of pre-IPO connected transactions. In 5 cases (33.3%), the sponsor had not identified all connected persons of the applicant, relying instead on a narrow definition that excluded parties connected to the applicant’s substantial shareholders. The SFC specifically criticised the use of “comfort letters” from the applicant’s legal counsel as a substitute for independent sponsor verification. The report explicitly referenced HKEX Listing Rule 14A.10 and the sponsor’s duty under paragraph 17.6 of the Code as the operative standards.

For sponsors, the key takeaway from the 2024 findings is that the SFC will now expect to see a documented CT review plan, a clear rationale for the scope of review, and a trail of evidence that the sponsor independently verified each material term of every identified CT. The SFC also expects the sponsor to consider whether a transaction, even if not technically a CT under the rules, has the substance of a connected arrangement — for example, a transaction with a party that is a close associate of a director but not formally captured by the definition.

The Sponsor’s Enhanced Review Obligations: A Three-Phase Framework

Phase One: Pre-Agreement Mapping and Connected Person Identification

The first and most critical phase begins before the sponsor signs the engagement letter. The sponsor must map the applicant’s entire connected person universe. This goes beyond the obvious directors and substantial shareholders. The definition of “connected person” under Chapter 14A includes associates of directors, which in turn captures family trusts, controlled entities, and in some cases, business partners with a history of joint ventures. The sponsor must also consider the 12-month look-back period: any person who was a director of the applicant within the 12 months preceding the application date remains a connected person for the purposes of Rule 14A.10.

A practical approach is to require the applicant to provide a full organisational chart showing all shareholders, directors, and their respective associates, extending to the ultimate beneficial owner level. The sponsor should then cross-reference this chart against the applicant’s transaction records for the 24-month period preceding the application (12 months of look-back plus 12 months of buffer). The SFC’s 2024 report emphasised that in one case, a sponsor had failed to identify a transaction with a company owned by the spouse of a director, which was subsequently found to be a connected transaction. The sponsor’s defence — that the spouse was not a director — was rejected because the definition of “associate” under Rule 14A.12 includes the spouse of a director.

Phase Two: Transaction-Level Verification and Pricing Benchmarking

Once the connected person universe is mapped, the sponsor must verify each identified CT at the transaction level. This is where the most common deficiencies arise. The sponsor must obtain and review the underlying contract, the payment records, the board resolutions (if any), and any third-party valuation or pricing justification. For transactions involving the acquisition or disposal of assets, the sponsor must benchmark the pricing against independent market data. For services agreements, the sponsor must assess whether the fees are consistent with arm’s length commercial terms.

The SFC’s 2024 findings specifically highlighted the problem of “bundled” transactions — where a single contract covers multiple services or assets, making it difficult to assess the fairness of individual components. In such cases, the sponsor is expected to unbundle the transaction and assess each component separately. If the sponsor cannot obtain sufficient evidence, the transaction must be disclosed as a connected transaction in the prospectus, with a clear statement that the sponsor was unable to fully verify its terms. This is not an admission of failure; it is a compliance requirement under paragraph 17.6 of the Code.

Phase Three: Prospectus Disclosure and Post-Listing Commitments

The prospectus must contain a clear and prominent section dedicated to connected transactions. This section should include: (i) a list of all CTs entered into within the 12-month pre-application period; (ii) the sponsor’s opinion on whether each CT was entered into on normal commercial terms and in the ordinary and usual course of business; (iii) a statement of the sponsor’s verification procedures; and (iv) any qualifications or limitations on the sponsor’s ability to verify. The HKEX’s Listing Decision LD143-2024 (October 2024) clarified that the sponsor must also disclose any CT that, while not individually material, becomes material when aggregated with other CTs of a similar nature.

Post-listing, the sponsor’s obligations do not automatically terminate. The HKEX’s Guidance Letter GL57-13 (updated January 2025) reminds sponsors that they retain a duty to ensure that the prospectus remains accurate and not misleading for a reasonable period after listing. If a material CT is discovered post-listing that should have been disclosed, the sponsor must immediately inform the HKEX and the SFC. Failure to do so can result in enforcement action under the Securities and Futures Ordinance (Cap. 571), Section 213.

Practical Compliance: Building a CT Review Workflow

Documenting the Review Plan and the Evidence Trail

The single most effective defence against an SFC investigation is a well-documented review plan and a complete evidence trail. The sponsor should prepare a written CT review plan at the start of the engagement, approved by the sponsor’s internal compliance committee. This plan should specify: (i) the scope of the connected person mapping exercise; (ii) the list of documents to be obtained for each identified CT; (iii) the pricing benchmarks to be used; (iv) the procedures for escalating unresolved issues; and (v) the timeline for completion.

Every step of the review must be documented in the sponsor’s working papers. This includes emails, meeting minutes, call notes, and any correspondence with the applicant’s management or legal counsel. The SFC’s 2024 report found that in 4 of the 15 engagements (26.7%), the sponsor had no contemporaneous record of its CT review work, relying instead on post-hoc summaries prepared after the SFC’s inquiry began. This is a critical failure: the SFC will treat the absence of contemporaneous documentation as evidence that the review did not occur.

The Role of Third-Party Experts and the Sponsor’s Independent Judgment

Sponsors frequently engage third-party experts — valuation firms, forensic accountants, or legal counsel — to assist with CT verification. This is acceptable, but the sponsor must not delegate its independent judgment. Paragraph 17.6 of the Code requires the sponsor to form its own reasonable belief about the accuracy of the prospectus. Relying solely on a third-party expert’s report without independently testing its assumptions or methodology is a breach of this duty.

The SFC’s 2024 report cited a case where the sponsor engaged a valuation firm to assess the fairness of a property acquisition from a connected person. The valuation report used a comparable sales approach but did not adjust for differences in property condition or location. The sponsor accepted the report without question. The SFC found that the sponsor had failed to exercise due diligence because it did not request the underlying comparable data or test the valuation assumptions. The sponsor was subsequently fined HKD 5 million and its licence was suspended for 6 months.

Handling Red Flags and the Duty to Escalate

If during the CT review the sponsor identifies a red flag — for example, a transaction with no apparent commercial rationale, a pricing discrepancy exceeding 15% from market benchmarks, or a counterparty that cannot be identified — the sponsor must escalate the issue internally and to the applicant’s board. The HKEX’s Listing Decision LD143-2024 states that a red flag that is not adequately resolved must be disclosed in the prospectus as a material risk factor.

The sponsor should maintain a red flag log, documenting each issue, the steps taken to investigate it, and the outcome. If the issue cannot be resolved, the sponsor must consider whether it can still form a reasonable belief that the prospectus is accurate. If not, the sponsor should consider withdrawing from the engagement. The SFC has made it clear that a sponsor cannot simply “disclaim” its way out of a deficient CT review. A qualified opinion in the prospectus is only acceptable if the sponsor has made all reasonable efforts to verify the transaction and has clearly explained the limitations of its work.

Closing Takeaways

1. Map the connected person universe at engagement commencement, using a 24-month look-back period and extending to all associates of directors and substantial shareholders, not just the named parties.

2. Document every verification step contemporaneously in the sponsor’s working papers, including emails, meeting minutes, and pricing benchmark analyses, to create a defensible evidence trail.

3. Unbundle bundled transactions and assess each component separately for arm’s length pricing, using independent market data rather than relying solely on management representations.

4. Do not delegate independent judgment to third-party experts; the sponsor must test the assumptions and methodology of any valuation or legal opinion relied upon.

5. Escalate and disclose all unresolved red flags in the prospectus as material risk factors, and consider withdrawal from the engagement if a reasonable belief in the prospectus’s accuracy cannot be formed.